A phase I trial of 5-day continuous infusion cisplatin and interferon α
✍ Scribed by Michael P. Gosland; Susan Goodin; Robert A. Yokel; Marietta Smith; William J. John
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 883 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Fourty-four evaluable patients were treated with 6-methylmercaptopurine riboside (MMPR) at a dose of 20 mg/m2/day X 5 by continuous IV infusion (days 1-5 and 5-fluorouracil (5-FU) on an escalating dose schedule of 300-1519 mg/m2/day X 5 by continuous IV infusion (days 2-6). Dose-limiting oral mucosi
In order to determine whether a simultaneous infusion of N-(phospho-n-acetyl)-L-aspartic acid (PALA) was able to increase the rate of antitumor response to 5-fluorouracil (5-FU), a pilot study was conducted. Of 10 evaluable patients with previously drug-untreated colorectal carcinoma, there were onl